Deepcell is helping to advance precision medicine by combining advances in AI, cell classification and capture, and single-cell analysis to deliver novel insights through an unprecedented view of cell biology. Spun out of Stanford University in 2017, the company has created unique, microfluidics-based technology that uses continuously learning AI to classify cells based on detailed visual features and sort them without inherent bias. The Deepcell platform maintains cell viability for downstream single-cell analysis and can be used to isolate virtually any type of cell, even those occurring at frequencies as low as one in a billion.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/19/22 | $73,000,000 | Series B |
Andreessen Horowitz Bow Capital Bridger Healthcare Partners Casdin Capital Horizons Ventures Jeff Dean Koch Disruptive Technologies  Matt Mcllwain | undisclosed |
